Angiogenesis as a target for tumor treatment

Oncology (Switzerland)

Volumn 54, Issue 3, 1997, Pages 177-184

  Gastl, Gunther ^a   Hermann, Thomas ^b   Steurer, Michael ^b   Zmija, Jörg ^b   Gunsilius, Eberhard ^a   Unger, Clemens ^b   Kraft, Andrea ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Angiogenesis; Angiogenic inhibitor; Neovascularization

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; AURINTRICARBOXYLIC ACID; BATIMASTAT; DISTAMYCIN A DERIVATIVE; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GENISTEIN; INTERFERON; INTERLEUKIN 12; METALLOPROTEINASE INHIBITOR; MINOCYCLINE; NITRIC OXIDE SYNTHASE INHIBITOR; PENICILLAMINE; PLASMINOGEN ACTIVATOR; PROTEINASE INHIBITOR; QUINOLINE DERIVATIVE; RETINOID; ROQUINIMEX; SURAMIN; TAMOXIFEN; THALIDOMIDE; VITAMIN D DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BASEMENT MEMBRANE; CANCER CHEMOTHERAPY; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEMANGIOMA; HUMAN; HUMAN CELL; META ANALYSIS; METASTASIS; NONHUMAN; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PATIENT SELECTION;

EID: 0030888879     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227685     Document Type: Article

References (69)

1. Folkman J: Tumor angiogenesis: Therapeutic implications, N Engl J Med 1971:285:1182-1186.
2. Folkman J: Tumor angiogenesis; in Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds): The Molecular Basis of Cancer, Philadelphia, Saunders, 1995, pp 206-232.
3. Bicknell R, Harris AL: Mechanisms and therapeutic implications of angiogenesis, Curr Opin Oncol 1996:8:60-65.
4. Marine D: Tumor angiogensis, The pivotal role of vascular endothelial growth factor, World J Urol 1996, in press.
5. Bouck N: Angiogenesis: a mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis, CancerTreat Res 1992:63:359-371.
6. Dameron KM, Volpert OV, Taisnky MA, Bouk N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1, Science 1994: 265:1582-1584.
7. Folkman J: Clinical applications of research on angiogenesis, N Engl J Med 1995:333:1757-1763.
8. Van Meir EG, Poverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells, Nat Genet 1994:8:171-176.
9. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogen-esis suppression, Nat Med 1995:1:27-31.
10. Fidler IJ, Ellis LM: The implications of angio-genesis for the biology and therapy of cancer metastasis, Cell 1994:79:185-188.
11. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool, J Clin Oncol 1995:13:765-782.
12. Hori A, Sasada R, Matsutani E, N’aito K, Saku-ra Y, Fujita T, Kozei Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor, Cancer Res 1991:51:6180-6184.
13. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature 1993:362:841-844.
14. Olson KA, Fett JW, French TC, Key ME, Val-lee BL: Angiogenin antagonists prevent tumor growth in vivo, Proc Natl Acad Sei USA 1995: 92:442-446.
15. Braddock PS, Hu De, Fan TDP, Stratford U, Harris AL, Bicknell R: A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions, Br J Cancer 1994;69:890-898.
16. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angio-suppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, proliferation, and induction of urokinase-type plasminogen activator, Canccr Res 1994:54:2654-2660.
17. Myers C, Cooper M, Stein C, LaRocco R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan MW: Suramin: a novel growth factor antagonist with activity in hormone-refractory prostate cancer, J Clin Oncol 1992:10:881-889.
18. Tanaka NG, Sakamoto N, lnouc K, Korenaga H, Kadoya S, Ogawa H, Osada Y: Antitumor effect of an antiangiogenic polysaccharide from an Arthrobacter species w ith or without a steroid, Cancer Res 1989:49:6727-6730.
19. Maione TE, Gray GS, Petro J, Hunt AJ, Don-ner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides, Science 1990;247:77-79.
20. O’Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice, Nat Med 1996;2:689-692.
21. Majewski S, Polakowski I, Marczak M, Ja-blonska S: The effect of retinoids on lymphocyte- and transformed cell line-induced angiogenesis, Clin Exp Dermatol 1986:2:317-318.
22. Oikawa T, Hirotani K, Ogasawara H, Kataya-ma T, Nakamura O, Iwaguchi T, Hiragun A: Inhibition of angiogenesis by vitamin Di analogues, EurJ Pharmacol 1990:178:247-250.
23. Shokravi MT, Marcus DM, Alrov J, Egan K, Saomil MA, Albert DM: Vitamin D inhibits angiogensis in transgenic murine retinoblastoma, Invest Ophthalmol Vis Sci 1995:36:83-87.
24. Antoine N, Grcimcrs R, De-Roanne C, Kusaka M, Heinen E, Simar U, Castronovo V: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle, Cancer Res 1994:54:2073-2076.
25. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Angioinhi-bins: synthetic analogues of fumagillin which inhibit angiogenesis and suppress tumour growth, Nature 1990;348:555-557.
26. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Harley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linom-ide, Cancer Res 1993;53:1833-1837.
27. Gagliardi A, Collins DC: Inhibition of angiogenesis bv antiestrogens, Cancer Res 1993:53: 533-535.
28. Matsubara T, Saura R, Hirohata K, Ziff M: Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by -penicillamine, J Clin Invest 1989:83:158-167.
29. Fotsis T, Pepper M, Adlercreutz H, Flcisch-mann G, Hase T, Montesano R, Schweigerer L: Genistein, a dietary-derived inhibitor of in vitro angiogenesis, Proc Natl Acad Sci USA 1993;90:2690-2694.
30. D’Amato RJ, Loughman MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis, Proc Natl Acad Sci USA 1994;91: 4082-4085.
31. Sidkv YA, Borden EC: Inhibition of angiogenesis by interferons: Effects on tumor- and lym-phocyle-induccd vascular responses, Cancer Res 1987:47:5155-5161.
32. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by intcrleukin-12, J Natl Cancer Inst 1995;87:581-586.
33. Brooks PC, Montgomery AM, Rosenfeld M, Reisfcld RA, Hu T, Klier G, Chcresh DA: Inte-grin avβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, Cell 1994:79:1157-1164.
34. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloprotei-nasc inhibitor decreases tumor burden and prolongs survival of mice with human ovarian cancer xenografts, Cancer Res 1993:53:2087-2091.
35. Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline, Cancer Res 1991; 51:672-675.
36. Mueller BM, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice, Proc Natl Acad Sci USA 1995:92:205-209.
37. Gagliardi AR, Collins DC: Inhibition of angiogenesis by aurintricaboxylic acid, Anticancer Res 1994:14:475-479.
38. Ziche M, Morbidelli L, Masoni E, Amerini S, Granger HJ, Maggi CA, Gepetti P, Ledda F: Nitric oxide mediates angiogenesis in vivo and endothelial ceil growth and migration in vitro promoted by substance P, J Clin Invest 1994; 94:2036-2044.
39. Weinstat-Saslow DL, Zabrenetzky VS, Van Houtte K, Frazier WA, Roberts DD, Steeg PS: Transfection of thrombospondin complementary' DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential and angiogenesis, Cancer Res 1994: 54:6504-6511.
40. Greer P, Haigh J, Mbamalu G, Khoo W, Bernstein A, Pawson T: The fps/fes protein tyrosine kinase promotes angiogenesis in transgenic mice, Mol Cell Biol 1994:14:6755-6763.
41. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdzar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-reglation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy, Clin Cancer Res 1995; 1:1623-1634.
42. Rettig WJ, Garinchesa P, Healey JH, Su SL, Jaffe EA, Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothcl ial cells in human cancer, Proc Natl Acad Sci USA 1992;89:10832-10836.
43. Carnemotla B, Balza E, Siri A, Zardi L, Nicro-tra MR, Bigotti A, Natali PG: A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors, J Cell Biol 1989;108:1139-1148.
44. Plate KH, Breicr G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature 1992;359:845-848.
45. Dvorak HJ, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors - Concentration in tumor blood vessels, J Exp Med 1991; 174: 1275-1278.
46. Bicknell R: Vascular targeting and the inhibition of angiogenesis, Ann Oncol 1994;5:45-50.
47. Fan TP, Jaggar R, Bicknell R: Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting, Trends Pharmacol Sci 1995;16:57-66.
48. Folkman J, Ingber DE: Angiostatic steroids: Method of discovery and mechanism of action, AnnSurg 1987;206:373-384.
49. Gengrinovitch S, Greenberg SM, Cohen T, Gi-tay-Gorcn H, Rockwell P, Maione TE, Levi BZ, Neufcld G: Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using concurrent mechanisms, J Biol Chem 1995;270:15059-15065.
50. Staddon A, Henry D, Bonnem E: A randomized dose finding study of recombinant human platelet factor-4 in cutaneous AIDS-related Kaposi's sarcoma (abstract), Proc Am Soc Clin Oncol 1994:13:50.
51. 5 and their combination, Cancer Lett 1993:75:35-39.
52. Pienta KJ, Nguyen NM, Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinimide, Cancer Res 1993:53: 224-226.
53. Lingen MW, Polvcrini PJ, Bouck NP: Synergy between retinoic acid and interferon-a in inhibiting angiogenesis induccd by head and ncck squamous cell carcinoma (abstract), Proc Am Assoc Cancer Res 1996:37:60.
54. Moore DM, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, Paredes-Espinoza M, Krakoff IH: Retinoic acid and interferon in human cancer: Mechanistic and clinical studies, Semin Hematol 1994:31:31-37.
55. Bollag W: Experimental basis of cancer combination chemotherapy with retinoids, cytokincs. 1,25-dihydroxy vitamin D3, and analogs, J Cell Biochem 1994:56:427-435.
56. Takamiya Y, Brem H, Ojeifo J, Mineta T, Mar-tuza RL: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo, Neurosurgery 1994;34:869-875.
57. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S: Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential, Cancer 1996:77:1736-1740.
58. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons a and (5 dow'n-regulate the expression of basic fibroblast growth factor in human carcinomas, Proc Natl Acad Sci USA 1995;92:4562-4566.
59. Ezekowitz RAB, Mulliken JB, Folkman J: In-terferon-alpha-2a therapy for life-threatening hemangiomas of infancy, N Engl J Med 1992: 326:1456-1463.
60. Lawrence JA, Steeg PS: Mechanisms of tumor invasion and metastasis, World J Urol 1996, in press.
61. Matrisan LM: Metalloproteinases and their inhibitors in matrix remodelling, Trends Genet 1990:6:121-125.
62. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spec-taim of cancers, J Natl Cancer Inst 1994;86: 356-361.
63. Kraft A, Weindel K, Marth C, Schumacher P, Zmija J, Hermann T, Steurer M, Unger C, Marmò D, Gastl G: Vascular endothelial growth factor in serum and malignant ascites (abstract), Proc Am Assoc Cancer Res 1996:37: 58.
64. Wu CC, Lee CN, Chen TM, Shyn MK, Hsieh CY, Chen HY, Hsieh FJ: Incremental angio-gcnesis assessed by color Doppler ultrasound in the tumorigenesis of ovarian neoplasms, Cancer 1994;73:1251-1256.
65. Scopinaro F, Schillaci O, Scarpini M, Mingaz-zini PL, Di Macio L, Banci M, Danieli R, Zerili M, Limiti MR, Ccnt-Colella A: Technetium sestamibi: An indicator of breast cancer inva-sivencss, Eur J Nucl Med 1994:21:984-987.
66. Abramovitch R, Meir G, Neeman M: Neovascularization induced growth of implanted C6 glioma multiccllular spheroids: Magnetic resonance microimaging, cancer Res 1995;55: 1956-1962.
67. Teichcr BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H: Potentiation of cytotoxic cancer therapies by tnp-470 alone and with other antiangiogenic agents, Int J Cancer 1994;57:920-925.
68. Kato T, Sato K, Kakinuma H, Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor o-(chlo-roacetylcarbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice, Cancer Res 1994:54: 5143-5147.
69. Teichcr BA, Holden SA, Gulshan A, Korbut T, Menon K: Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma, Cancer Che-mother Pharmacol 1996:38:169-177.